News
EGRX
--
0.00%
--
Argatroban Market Size Report 2021 by Manufacturer Share, Price, Revenue, Gross Profit and Forecast to 2025
Apr 08, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Argatroban Market” report gives over all...
The Express Wire · 3d ago
Cancer Tubulin Inhibitors Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027
Apr 06, 2021 (Market Stats News via COMTEX) -- A new market research report titled "Global Cancer Tubulin Inhibitors Market 2021 Analysis and Industry...
Market Stats News · 4d ago
9.8% Return Seen to Date on SmarTrend Eagle Pharmaceut Call (EGRX)
Apr 06, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on February 16th, 2021 at $45.63. In...
marketwatch.com · 5d ago
Argatroban Market Size, Value and Volume By Types, Application, Opportunity, Trend, Share, Production, Import, Export, Consumption, Company Analysis 2021 – 2027
Apr 05, 2021 (The Expresswire) -- Global "Argatroban Market" report 2021 covers the present state of Market Share, CAGR, Revenue, Gross Market and the growth...
The Express Wire · 6d ago
Global Argatroban Market Size, Share, Value, and Competitive Landscape 2024
Heraldkeepers · 04/02 03:48
Argatroban Professional Survey Global Market Growth, Status and Outlook Research Report 2021
Apr 01, 2021 (Heraldkeepers) -- Argatroban is a prescription medicine used to treat the symptoms of blood clots in adults (Thrombocytopenia) and Percutaneous...
Heraldkeepers · 04/01 10:24
6.9% Return Seen to Date on SmarTrend Eagle Pharmaceut Call (EGRX)
Mar 25, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on February 16th, 2021 at $45.63. In...
marketwatch.com · 03/25 18:03
Global Alimta Market 2020 Applications, Market Size According to a Specific Product, Sales and Revenue by Region 2025
Mar 23, 2021 (CDN Newswire via Comtex) -- Global Alimta Market Growth 2020-2025 delivers an in-depth analysis of the market by value, by production capacity,...
CDN Newswire · 03/23 20:40
Cancer Tubulin Inhibitors Market 2020-2027: Abraxis Biosciences, Agensys, Amgen
pune, India, Tue, 23 Mar 2021 04:09:55 / Comserve Inc. / -- Global Cancer Tubulin Inhibitors Market 2020 Size, forecast, and overview of current market...
Comserve · 03/23 08:12
Bendamustine Market 2021 : Business Status by Top Key Companies, Market Size, Growth and Geographical Forecast Till 2026 with Top Countries Data
Mar 18, 2021 (The Expresswire) -- Global “Bendamustine Market" 2021-2026 Research Report provides key analysis on the market status of the Bendamustine...
The Express Wire · 03/19 01:55
Top Pharmaceutical Stocks for Q2 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2 2021.
Investopedia · 03/15 21:08
Global Bendamustine Market Size 2021 Analysis By Industry Share, End-User Demand, Size Estimation, Growth Factors, Production, Industry Statistics, Overview, and Forecast Report till 2026
The Express Wire · 03/10 05:27
Argatroban Market Size 2021 By Share, Industry Statistics, Global Trends Evaluation, Geographical Segmentation, Business Challenges and Investment Opportunities Analysis till 2026
Mar 09, 2021 (The Expresswire) -- The report provides revenue of the globalArgatroban Market for the period 2016 and 2026, considering 2020 as the base year...
The Express Wire · 03/09 05:50
10-K: EAGLE PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 03/05 14:09
Is Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Trading At A 21% Discount?
Today we will run through one way of estimating the intrinsic value of Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) by...
Simply Wall St. · 03/03 05:23
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates
Zacks.com · 03/03 02:33
DJ Eagle Pharmaceuticals, Inc. CEO Scott Tarriff on Q4 2020 Results -- Earnings Call Transcript >EGRX
Dow Jones · 03/02 21:07
8-K: EAGLE PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- 0000827871 false 0000827871 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/02 20:07
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates
Zacks.com · 03/02 13:15
BRIEF-Eagle Pharmaceuticals Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.96
reuters.com · 03/02 12:05
Webull provides a variety of real-time EGRX stock news. You can receive the latest news about Eagle Pharms through multiple platforms. This information may help you make smarter investment decisions.
About EGRX
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.